Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immunowork LLC is navigating the patent prosecution process for its portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio data shows 1 pending office action. This single action requires attention to move the application toward issuance or further review. In the complex field of biotechnology, having 1 pending office action represents a specific, localized effort in the company's broader intellectual property strategy.
The examination process is highly focused, involving 1 distinct examiner and 1 distinct art unit. This concentration suggests that the technical subject matter is being reviewed by a specialized team within the patent office. STONEBRAKER, ALYSSA RAE is the busiest examiner associated with this portfolio. This examiner is responsible for 1 busiest examiner pending action. Because this 1 busiest examiner pending action accounts for the total volume of pending actions, the company's current prosecution success is tied to the interactions with this specific individual.
The use of 1 distinct art unit for the 1 pending office action ensures that the examination remains within a consistent technical framework. Practitioners can focus their efforts on the specific requirements of STONEBRAKER, ALYSSA RAE to resolve the pending matter. This level of focus in the Biotechnology & Pharmaceuticals sector allows for a very targeted approach to overcoming any objections raised by the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18631559 | METHOD OF IDENTIFYING AND TREATING MEMBRANOUS NEPHROPATHY | STONEBRAKER, ALYSSA RAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18631559 | METHOD OF IDENTIFYING AND TREATING MEMBRANOUS NEPHROPATHY | STONEBRAKER, ALYSSA RAE | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18631559 | METHOD OF IDENTIFYING AND TREATING MEMBRANOUS NEPHROPATHY | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Final Rejection | — | Pending | Apr 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunowork LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alyssa Rae Stonebraker has the most, with 1 of Immunowork LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
